The estimated Net Worth of Phillips Courtney is at least $22.5 mil dollars as of 1 September 2023. Ms Courtney owns over 7,061 units of Atreca Inc stock worth over $4,539 and over the last 5 years she sold BCEL stock worth over $17,934.
Ms has made over 3 trades of the Atreca Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently she sold 7,061 units of BCEL stock worth $2,613 on 1 September 2023.
The largest trade she's ever made was selling 7,061 units of Atreca Inc stock on 1 September 2023 worth over $2,613. On average, Ms trades about 1,757 units every 36 days since 2019. As of 1 September 2023 she still owns at least 50,431 units of Atreca Inc stock.
You can see the complete history of Ms Courtney stock trades at the bottom of the page.
Courtney J. Phillips J.D. is the Gen. Counsel & Corp. Sec. at Atreca Inc.
Ms D is 46, she's been the Gen. Counsel & Corp. Sec. of Atreca Inc since . There are 3 older and no younger executives at Atreca Inc. The oldest executive at Atreca Inc is Dr. Tito A. Serafini Ph.D., 58, who is the Founder, Chief Strategy Officer & Director.
Phillips's mailing address filed with the SEC is C/O ATRECA, INC., 835 INDUSTRIAL RD., SUITE 400, SAN CARLOS, CA, 94070.
Over the last 5 years, insiders at Atreca Inc have traded over $4,571,843 worth of Atreca Inc stock and bought 6,001 units worth $76,740 . The most active insiders traders include Group, Llc Green Jeremy Red..., Bros. Advisors Lp Baker Bro... y Harbor Master Investors (Ca.... On average, Atreca Inc executives and independent directors trade stock every 20 days with the average trade being worth of $991. The most recent stock trade was executed by John A Orwin on 11 April 2024, trading 1 units of BCEL stock currently worth $0.
atreca is a biotechnology company that develops novel therapeutics through a deep understanding of the human immune response, with a focus on innovative novel cancer immunotherapeutics. with its immune repertoire capture™ (irc™) technology, atreca has an unparalleled insight into how cancer patients’ immune responses can drive better clinical outcomes. atreca was founded by scientists, industry experts, and investors who share the vision that unlocking the immune response of today’s patients is the key to creating a new generation of therapies. atreca is looking for talented, entrepreneurial people who are dedicated to making a positive impact on human health. if you are interested in becoming part of the atreca team, our open positions can be found at: http://www.atreca.com/careers/
Atreca Inc executives and other stock owners filed with the SEC include: